Figure 2

Cumulative number of trials registered on ClinicalTrials.gov, by calendar time, 2005–2014. The cumulative number of trials is stratified by use of enrichment design and randomization regrouped into six categories: nonrandomized and randomized trials enriched on the same pharmacogenomics as mentioned in the label (dark and light red, respectively), nonrandomized and randomized trials enriched on another pharmacogenomic (dark and light blue, respectively), and nonrandomized and randomized nonenriched trials (dark and light green, respectively). Red areas represent trials that are restricted to the biomarker mentioned in the label; blue, trials enriched on another biomarker; and green, nonenriched trials. Lighter areas represent randomized trials, darker areas represent nonrandomized trials. The charts are sorted by number of trials. Vertical axes go up to 200 for the first row, 60 for the second, 40 for the third, and 800 for the last row. Dates of first submission and first approval by the US Food and Drug Administration (FDA) or European Medicines Agency (EMA) are shown by red and black vertical arrows, respectively.